ERBB2 and breast carcinoma: CircGFRA1/miR-1228/FSP1 axis participates in the development of HER2 positive breast cancer through ferroptosis pathway, and is a potential target for clinical treatment of HER2 positive breast cancer (Bazhabayi et al., 2021).